2. DexCom, Inc. (NASDAQ:DXCM)
On June 15, 2026, Piper Sandler analyst Matt O’Brien raised the firm’s price target on DexCom, Inc. (NASDAQ:DXCM) to $88 from $75 and maintained an Overweight rating on the shares. O’Brien said Piper Sandler updated some of its models to better align with quarterly cadence, company guidance, and consensus estimates. For DexCom, the firm cited greater visibility into the long-term pipeline and catalyst cadence supporting sustained, outsized top-line growth.
On June 12, 2026, the U.S. Food and Drug Administration cleared DexCom, Inc.’s (NASDAQ:DXCM) Stelo Glucose Biosensor System for marketing as the first over-the-counter continuous glucose monitor for children. The integrated CGM is indicated for people two years of age and older who do not use insulin. The FDA had previously cleared Stelo OTC for individuals 18 years and older in March 2024. Michelle Tarver, Director of the Center for Devices and Radiological Health, said the clearance reflects the FDA’s commitment to supporting innovation for pediatric patients.
On June 10, 2026, TD Cowen analyst Joshua Jennings raised the firm’s price target on DexCom, Inc. (NASDAQ:DXCM) to $95 from $75 and maintained a Buy rating on the shares. Jennings said DexCom appears to be at the forefront of the T2NIT coverage expansion initiative and that CONNECT represents a compelling dataset for payers. TD Cowen views DexCom as a share gainer in the U.S. T2NIT market, while noting that incremental access should benefit all players because of the size of the opportunity.
DexCom, Inc. (NASDAQ:DXCM) designs, develops, and commercializes continuous glucose monitoring systems for diabetes and metabolic health management in the United States and internationally.
